Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)

Tatsunori Shimoi,1 Akihiko Shimomura,1 Tadahiko Shien,2 Yukari Uemura,3 Hiroaki Kato,4 Masahiro Kitada,5 Tatsuya Toyama,6 Tomohiko Aihara,7 Hirofumi Mukai8 1Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; 2Department of Breast and Endocrine Surgery, Okayama...

Descrición completa

Detalles Bibliográficos

Principais autores:	Shimoi T, Shimomura A, Shien T, Uemura Y, Kato H, Kitada M, Toyama T, Aihara T, Mukai H
Formato:	Artigo
Idioma:	Inglês
Publicado:	Dove Medical Press 2018-02-01
Series:	Open Access Journal of Clinical Trials
Assuntos:	aromatase inhibitor estrogen receptor
Acceso en liña:	https://www.dovepress.com/open-label-phase-ii-study-of-everolimus-plus-endocrine-therapy-in-post-peer-reviewed-article-OAJCT
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!